Author:
Tawfik Marwa Mohammed Hasan,Monib Ahmed Mohamed,Yassin Aya,Ali Susan Adil
Abstract
Abstract
Background
Accurate radiologic assessment of treatment response in lymphomas is important for helping the clinicians to properly evaluate effectiveness of treatment and consequently guide therapeutic management of these patients. Imaging tools based on anatomic response are suboptimal in detecting functional changes in tumors resulting after early effective treatment. Recently, with the development of 18F-FDG PET/CT, both functional and anatomic information has been integrated for assessing treatment response in both solid tumors and hematologic malignancies. The aim of this study was to compare therapeutic response in lymphoma patients using both RECIST 1.1 and PERCIST 1.0 criteria.
Results
Among the included 33 lymphoma patients, RECIST 1.1 and PERCIST 1.0 classifications of therapeutic response were concordant in 20 patients (60.6%) and discordant in 13 patients (39.4%), with a tendency of RECIST 1.1 to downgrade the tumor response in 12/13 patients (P value < 0.001).
Conclusion
The recently applied PERCIST 1.0 is efficient and more accurate than RECIST 1.1 to assess treatment response in lymphoma patients, which is subsequently affecting further management of these patients.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging
Reference22 articles.
1. Baratto L, Jegede O, Hong F, Kahl B, Evens A, Quon A (2016) Comparison between LUGANO, EORTC, PERCIST and IHP criteria at interim PET in patients with follicular non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 43(20):S30–S31
2. Maffione AM, Paolini R, Rodella E, Ambrosio C, Rampin L, Lisato LC, Rubello D (2015) Response criteria for malignant lymphoma. Nucl Med Commun 36(4):398–405
3. Moghbel MC, Kostakoglu L, Zukotynski K, Chen DL, Nadel H, Niederkohr R, Mittra E (2016) Response assessment criteria and their applications in lymphoma: part 1. J Nucl Med 57(6):928–935
4. Ali SA, Abd Elkhalek YI (2016) Added value of combined 18F-FDG PET/CT for detection of osseous metastases in cancer patients. EJRNM 47(2):453–458
5. Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480–508
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献